p53 aberrations in oral submucous fibrosis and oral squamous cell carcinoma detected by immunocytochemistry and PCR-SSCP

Journal of Oral Pathology and Medicine

Volumn 27, Issue 2, 1998, Pages 72-77

  Trivedy, C ^a   Warnakulasuriya, K A A S ^a   Tavassoli, M ^a   Steingrimsdottir, H ^a   Penhallow, J ^a   Maher, R ^a   Johnson, N W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Immunocytochemistry; Oral cancer; P53; PCR SSCP; Risk markers; Submucous fibrosis

Indexed keywords

CYTOGENETICS; GENETIC ANALYSIS; IMMUNOANALYSIS; MONOCLONAL ANTIBODY; PAKISTAN; POLYMERASE; PROTEIN P53; TUMOR SUPPRESSOR GENE;

EID: 0032006094     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.1998.tb02097.x     Document Type: Article

References (27)

1. MURTI PR, BHONSLE RB, PINDBORG JJ, DAFTARY DK, GUPTA PC, MEHTA FS. Malignant transformation rate in oral submucous fibrosis over a 17-year period. Community Dent Oral Epidemiol 1985; 15: 340-1.
2. MAHER R, LEE AJ, WARNAKULASURIYA KAAS, LEWIS JA, JOHNSON NW. Role of areca nut in the causation of oral submucous fibrosis: a case control study in Pakistan. J Oral Pathol Med 1994; 23: 65-9.
3. MURTI PR, BHONSLE RB, GUPTA PC, DAPTARY DK, PINDBORG JJ, MEHTA FS. Etiology of oral submucous fibrosis with special reference to the role of areca nut chewing. J Oral Pathol Med 1995; 24: 145-52.
4. HARVEY W, SCUTT A, MEGHJI S, CANNIFF JP. Stimulation of human buccal mucosa fibroblasts in vitro by betel nut alkaloids. Arch Oral Biol 1986; 31: 45-9.
5. VAN WYK C, OLIVIER A, DE MIRANDA CM, VAN DER BDL, GROBLER-RABIE AF. Observation on the effect of areca nut extracts on oral fibroblast proliferation. J Oral Pathol Med 1994; 23: 145-8.
6. SCULLY C. Oncogenes, tumour suppressors and viruses in oral squamous carcinoma. J Oral Pathol Med 1993; 22: 337-47.
7. FIELD JK. The role of oncogenes and tumour-suppressor genes in the aetiology of oral, head and neck squamous cell carcinoma. J R Soc Med 1995; 88: 35-9.
8. JOHNSON NW, WARNAKULASURIYA S, TAVASSOLI M. Hereditary and environmental factors; clinical and laboratory risk markers for head and neck, especially oral, cancer and precancer. Eur J Can Prev 1996; 5: 5-17.
9. HARRIS CC. The 1995 Walter Hubert Lecture - molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene Br J Cancer 1996; 73: 261-9.
10. SAKAI E, TSUCHIDA N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumour-suppressor genes. Oncogene 1992; 7: 927-33.
11. WARNAKULASURIYA KAAS, JOHNSON NW Expression of p53 mutant nuclear oncoprotein in oral carcinoma and potentially malignant oral lesions. J Oral Pathol Med 1992; 21: 401-5.
12. STEINGRIMSDOTTIR H, PENHALLOW J, FARZANEH F, JOHNSON N, TAVASSOLI M. Detection of p53 mutations in oral cancer samples using a sensitive PCR-SSCP method. Biochem Soc Trans 1997; 25. 315-8.
13. GREENBLATT MS, BENNETT WP, HOLLSTEIN M, HARRIS CC. Mutations in the p53 tumour suppressor gene: clues to cancer aetiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
14. MOYRET C, THEILLET C, PUIG PL, MOLES JP, THOMAS JP, HAMELIN R. Relative efficiency of denaturing gradient gel electrophoresis and single strand conformation polymorphism in the detection of mutations in exons 5 to 8 of the p53 gene. Oncogene 1994; 9: 1739-43.
15. rd international congress on oral cancer, Madras. Oral Oncology. Vol IIIA. Delhi: MacMillan, 1994; 195-8.
16. WARNAKULASURIYA KAAS, JOHNSON NW p53 overexpression in oral carcinoma: divergence in different populations and some caveats in immunohistochemistry. In: WARNER JA, LIPPERT BM, RUDERT HH, eds. Head and neck cancer. Advances in basic research. Holland. Elsevier. 1996; 307-11.
17. DOWELL SP, OGDEN GR. The use of antigen retrieval for immunohistochemical detection of p53 overexpression in malignant and benign oral mucosa: a cautionary note. J Oral Pathol Med 1996; 25: 60-4.
18. CALZOLARI A, CHIARELLI I, BIANCHI S, et al. Immunohistochemical vs molecular biology methods. Complementary techniques for effective screening of p53 alterations in head and neck cancer. Am J Clin Pathol 1997; 107: 7-11.
19. JACQUEMIER J, MOLES JP, PENAULT-LLORCA, et al. p53 Immuno-histochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer 1994; 69: 846-52.
20. ATULA S, KURVINEN K, GRENMAN R, SYRJANEN S. SSCP pattern indicative for p53 mutation is related to advanced stage and high-grade of tongue cancer. Eur J Cancer B Oral Oncol 1996; 32: 222-9.
21. SJOGREN S, INGANAS M, NORBEG T, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996, 88: 173-82.
22. MITSUDOMI T, STEINBERG SM, NAU MM, et al. P53 gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992; 7: 171-80
23. OGDEN GR, HALL PA. Field change, clonality, and early epithelial cancer: possible lessons from p53. J Pathol 1997; 181: 127-9.
24. HAYASHI K, YANDELL DW. How sensitive is PCR-SSCP? Hum Mutat 1993: 2: 338-46.
25. JENG JH, LAN WH, HAHN LJ, HSIEH CC, KUO MYP. Inhibition of the migration, attachment, spreading, growth and collagen synthesis of human fibroblasts by arecoline, a major areca alkaloid, in vitro. J Oral Pathol Med 1996; 25: 371-5.
26. HAINAUT P, ROLLEY N, DAVIES M, MILNER J. Modulation by copper of p53 conformation and sequence-specific DNA binding role for Cu(II)/Cu (I) redox mechanism. Oncogene 1995; 10: 27-36.
27. TRIVEDY C, BALDWIN D, WARNAKULASURIYA KAAS, JOHNSON NW, PETERS TJ. Copper content in Areca catechu (betel nut) products and oral submucous fibrosis. Lancet 1997; 449: 1447.